Current trials: Mantle Cell Lymphoma18

The following clinical trials are currently offered in Germany in this group. More about Mantle Cell Lymphoma

18 matching trials

CHARLYActive, not recruiting

Cyclophosphamide to Reduce Complications Following Haploidentical Stem Cell Transplantation

If non-Hodgkin lymphoma (NHL) cannot be controlled with standard therapy (refractory), a stem cell transplant from a compatible donor may be recommended. In a so-called haploidentical stem cell transplant, the immunological similarity between the donor and the recipient is lower, and rejection reactions may occur as a complication of the transplant. This risk could potentially be reduced by administering a high dose of the drug cyclophosphamide. The aim of the study is to investigate whether high-dose cyclophosphamide administered after a haploidentical stem cell transplant can prolong disease-free survival and reduce the risk of rejection reactions. Women and men aged 18–65 with relapsed or refractory NHL who are receiving a haploidentical allogeneic stem cell transplant are eligible to participate in this study.

18–65 years · Relapsed / refractory · Phase II

BGB-16673-101Recruiting

New treatment approach (drug: BGB-16673) as an adjunct to standard therapy with BTK inhibitors for various B-cell lymphomas

B-cell non-Hodgkin lymphomas (NHL) are malignant diseases of the lymphatic system for which, in certain cases, therapy with a Bruton’s tyrosine kinase inhibitor (BTK inhibitor) is a treatment option. A new mechanism of action (drug: BGB-16673) does not inhibit BTK but instead targets its destruction. The goal of the CaDAnCe-101 study is to investigate the optimal dosage, safety, and efficacy of the drug BGB-16673. Patients aged 18 and older with a variety of different NHLs are eligible to participate in the study. There must be no involvement of the central nervous system (CNS).

18 years and older · Relapsed / refractory · Phase I/II

ELM-2Recruiting

A new antibody (Odronextamab) for the treatment of B-cell non-Hodgkin lymphomas in patients who have already received prior treatment

B-cell non-Hodgkin lymphomas (NHL) are malignant diseases of the lymphatic system that can occur in various subtypes. Standard treatment often consists of immunochemotherapy; however, the disease may remain active (refractory) or become active again (recurrence). Odronextamab is a new antibody that targets cancer cells while simultaneously stimulating the immune system (bispecific). It is already approved for treatment in certain situations. The ELM-2 study is investigating the efficacy and safety of this new antibody (odronextamab). The study is open to women and men aged 18 and older who have follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), or another subtype of B-cell NHL, and whose disease is either refractory or has relapsed.

18 years and older · Relapsed / refractory · Phase II

MK-1026-003Recruiting

New Drug (Nemtabrutinib) for the Treatment of Various B-Cell Non-Hodgkin Lymphomas

B-cell non-Hodgkin lymphomas (NHL) are malignant diseases of the lymphatic system for which, in certain cases, therapy with a so-called Bruton’s tyrosine kinase inhibitor (BTK inhibitor) is a treatment option. BTK inhibitors specifically target the metabolism of cancer cells and inhibit their growth. This study is investigating the optimal dosage, safety, and efficacy of a new BTK inhibitor called nemtabrutinib (MK-1026). Women and men aged 18 and older with certain types of NHL are eligible to participate in this study, including chronic lymphocytic leukemia (CLL/SLL), Richter syndrome, marginal zone lymphoma (MZL), mantle cell lymphoma (MCL), follicular lymphoma (FL), and Waldenström macroglobulinemia (WM).

18 years and older · Relapsed / refractory · Phase II

HD-CAR-1Recruiting

New CAR-T cell therapy for previously treated patients with ALL (children and adults) and various types of non-Hodgkin lymphoma

Acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL) are diseases of the blood and lymphatic system. A relatively new form of therapy is treatment with CAR-T cells, which has already been approved in some situations. There are various CAR-T cell therapies available. The goal of the HD-CAR-1 study is to investigate the appropriate dosage, safety, and efficacy of another new CAR-T cell therapy. Women and men aged 18 and older with ALL or NHL, as well as children aged 3 and older with ALL, are eligible to participate in this study if the disease has not responded adequately to prior treatments or has become active again.

3 years and older · Relapsed / refractory · Phase I/II

M22-132Recruiting

Epcoritamab, a new bispecific antibody used in combination with various medications to treat patients with non-Hodgkin lymphoma

Non-Hodgkin lymphomas (NHL) refer to a group of lymphomas in which white blood cells—lymphocytes—undergo malignant changes and proliferate rapidly. In addition to traditional immunochemotherapy, targeted drugs are increasingly being used, such as epcoritamab, a novel antibody that can bind to two cells simultaneously (bispecific). The goal of the M22-132 study is to evaluate the safety, tolerability, and efficacy of epcoritamab in combination with other approved medications. Eligible participants include women and men aged 18 and older who have one of the following forms of non-Hodgkin lymphoma: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), mantle cell lymphoma (MCL).

18 years and older · Relapsed / refractory · Phase I/II

17-BI-1206-02In preparation

Can a new drug enhance the effectiveness of rituximab—a standard treatment for non-Hodgkin lymphoma—if the disease becomes active again?

B-cell non-Hodgkin lymphomas (NHL) are a group of malignant blood cancers. The antibody rituximab is a commonly used drug for these diseases; however, treatment is not always effective (refractory), or a relapse (recurrence) may occur. The aim of this study is to investigate the tolerability and efficacy of the new drug BI-1206, an antibody, in combination with rituximab. Among other things, it is hypothesized that BI-1206 enhances the effect of rituximab. Men and women with so-called indolent NHL are eligible to participate: follicular lymphoma (FL), marginal zone lymphoma (MZL), and mantle cell lymphoma (MCL), who are at least 18 years old and have already received at least one line of treatment that included rituximab.

18 years and older · Relapsed / refractory · Phase I/II

MK-2140-006Active, not recruiting

Study of the drug zilovertamab vedotin (MK-2140) as monotherapy and in combination with nemtabrutinib in patients with previously treated B-cell non-Hodgkin lymphoma

B-cell non-Hodgkin lymphomas refer to a group of lymphomas in which a type of white blood cell undergoes malignant changes. Zilovertamab vedotin is an antibody-drug conjugate that has not yet been approved; it specifically targets cancer cells and is currently being evaluated in various clinical trials. The goal of the MK-2140-006 study is to evaluate the safety, tolerability, and efficacy of zilovertamab—both as a monotherapy and in combination with the new, as-yet-unapproved drug nemtabrutinib (a BTK inhibitor). Eligible participants include women and men aged 18 and older with one of the following B-cell lymphomas: mantle cell lymphoma (MCL), Richter syndrome, or follicular lymphoma (FL). Participants must have either failed to respond to prior treatment (refractory) or have experienced a recurrence of the disease.

18 years and older · Relapsed / refractory · Phase II

EMCL RegistryRecruiting

A European Registry for Mantle Cell Lymphomas

Mantle cell lymphoma (MCL) is a rare malignant disease, which makes it difficult to conduct studies with sufficient scientific validity for all treatment scenarios. The goal of the EMCL Registry study is to establish a European registry for patients and to collect data that will contribute to the further development of medical care for patients with MCL. Women and men aged 18 and older who have been diagnosed with mantle cell lymphoma are eligible to participate in the study.

18 years and older · First line · Phase IV

CC-5013-MCL-005

Study to Evaluate the Association Between Lenalidomide and Tumor Flare Reactions and High Tumor Burden in Patients with Relapsed or Refractory Mantle Cell Lymphoma

Mantle cell lymphoma is a type of lymphoma that can vary greatly in its response to treatment. Lenalidomide can be used to treat relapses or patients who did not respond to initial treatment (refractory). The goal of the study is to investigate and characterize the relationship between lenalidomide and the so-called tumor flare reaction as well as tumor burden in people with relapsed/refractory mantle cell lymphoma. No drug or therapy is being tested in this study. Patients who have received at least one dose of lenalidomide and are at least 18 years old are eligible to participate in the study.

18 years and older · Relapsed / refractory